Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
195
|
Created
|
01/20/13
|
Type
|
Free
|
Moderators |
"AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery," said Nevan Elam, AntriaBio's President and CEO. "AB101 may offer significant advantages over basal insulin products sold by Sanofi-Aventis and Novo Nordisk, which together sell more than $7B annually."